Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Functional Selectivity of Allosteric Interactions within G Protein–Coupled Receptor Oligomers: The Dopamine D1-D3 Receptor Heterotetramer
Xavier Guitart, Gemma Navarro, Estefanía Moreno, et al.
Molecular Pharmacology (2014) Vol. 86, Iss. 4, pp. 417-429
Open Access | Times Cited: 116

Showing 26-50 of 116 citing articles:

Temporal reprogramming of calcium signalling via crosstalk of gonadotrophin receptors that associate as functionally asymmetric heteromers
Kim Jonas, S. Chen, Matilda Virta, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 57
Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure
Marta Busnelli, Gunnar Kleinau, Markus Muttenthaler, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 15, pp. 7152-7166
Open Access | Times Cited: 56
Targeting the dopamine D3 receptor: an overview of drug design strategies
Antoni Cortés, Estefanía Moreno, Mar Rodríguez-Ruiz, et al.
Expert Opinion on Drug Discovery (2016) Vol. 11, Iss. 7, pp. 641-664
Closed Access | Times Cited: 51
A Significant Role of the Truncated Ghrelin Receptor GHS-R1b in Ghrelin-induced Signaling in Neurons
Gemma Navarro, David Aguinaga, Edgar Angelats, et al.
Journal of Biological Chemistry (2016) Vol. 291, Iss. 25, pp. 13048-13062
Open Access | Times Cited: 47
Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection
Federica Bono, Veronica Mutti, Chiara Fiorentini, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1016-1016
Open Access | Times Cited: 39
Receptor dimers and biased ligands: Novel strategies for targeting G protein-coupled receptors
Wenkai Liu, Dexiu Wang, Luoqi Wang, et al.
Pharmacology & Therapeutics (2025), pp. 108829-108829
Closed Access
Intracellular Calcium Levels Determine Differential Modulation of Allosteric Interactions within G Protein-Coupled Receptor Heteromers
Gemma Navarro, David Aguinaga, Estefanía Moreno, et al.
Chemistry & Biology (2014) Vol. 21, Iss. 11, pp. 1546-1556
Open Access | Times Cited: 46
Dopamine D1 and D3 receptor polypharmacology as a potential treatment approach for substance use disorder
Ewa Galaj, Scott Ewing, Robert Ranaldi
Neuroscience & Biobehavioral Reviews (2018) Vol. 89, pp. 13-28
Closed Access | Times Cited: 42
Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders
Akinori Nishi, Takahide Shuto
Expert Opinion on Therapeutic Targets (2017) Vol. 21, Iss. 3, pp. 259-272
Closed Access | Times Cited: 40
Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer
Daniel Pulido, Verònica Casadó-Anguera, Laura Pérez‐Benito, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 20, pp. 9335-9346
Open Access | Times Cited: 40
Revealing Adenosine A2A-Dopamine D2 Receptor Heteromers in Parkinson’s Disease Post-Mortem Brain through a New AlphaScreen-Based Assay
Víctor Fernández‐Dueñas, Maricel Gómez‐Soler, Marta Valle-León, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 14, pp. 3600-3600
Open Access | Times Cited: 40
Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat
Nicole Chambers, Samantha M. Meadows, Anne Taylor, et al.
Neuroscience (2019) Vol. 409, pp. 180-194
Closed Access | Times Cited: 39
Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease
David Moreno‐Delgado, Mar Puigdellívol, Estefanía Moreno, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 32
Cell-Type-Specific Adaptions in Striatal Medium-Sized Spiny Neurons and Their Roles in Behavioral Responses to Drugs of Abuse
Marie‐Charlotte Allichon, Vanesa Ortiz, Paula A. Pousinha, et al.
Frontiers in Synaptic Neuroscience (2021) Vol. 13
Open Access | Times Cited: 27
Functional and pharmacological role of the dopamine D4 receptor and its polymorphic variants
Sergi Ferré, Annabelle M. Belcher, Jordi Bonaventura, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 21
Preferential Gs protein coupling of the galanin Gal1 receptor in the µ-opioid-Gal1 receptor heterotetramer
Paulo Alexandre de Oliveira, Estefanía Moreno, Nil Casajuana‐Martin, et al.
Pharmacological Research (2022) Vol. 182, pp. 106322-106322
Open Access | Times Cited: 20
The D3 dopamine receptor: From structural interactions to function
Chiara Fiorentini, Paola Savoia, Federica Bono, et al.
European Neuropsychopharmacology (2014) Vol. 25, Iss. 9, pp. 1462-1469
Closed Access | Times Cited: 38
Bidirectional allosteric interactions between cannabinoid receptor 1 (CB 1 ) and dopamine receptor 2 long (D 2L ) heterotetramers
Amina M. Bagher, Robert B. Laprairie, James Thomas Toguri, et al.
European Journal of Pharmacology (2017) Vol. 813, pp. 66-83
Closed Access | Times Cited: 38
Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists
Wei Xu, Xiaozhao Wang, Aaron M. Tocker, et al.
ACS Chemical Neuroscience (2016) Vol. 8, Iss. 3, pp. 486-500
Open Access | Times Cited: 37
Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron
Marla Rivera-Oliver, Estefanía Moreno, Yocasta Álvarez-Bagnarol, et al.
Molecular Neurobiology (2018) Vol. 56, Iss. 2, pp. 797-811
Open Access | Times Cited: 37
Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia
Kathryn Lanza, Samantha M. Meadows, Nicole Chambers, et al.
Neuropharmacology (2018) Vol. 138, pp. 304-314
Open Access | Times Cited: 37
Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area
Estefanía Moreno, César Quiroz, William Rea, et al.
Journal of Neuroscience (2016) Vol. 37, Iss. 5, pp. 1176-1186
Open Access | Times Cited: 35
Dopamine D3 and acetylcholine nicotinic receptor heteromerization in midbrain dopamine neurons: Relevance for neuroplasticity
Leonardo Bontempi, Paola Savoia, Federica Bono, et al.
European Neuropsychopharmacology (2017) Vol. 27, Iss. 4, pp. 313-324
Closed Access | Times Cited: 34
Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens
Xavier Guitart, Estefanía Moreno, William Rea, et al.
Molecular Neurobiology (2019) Vol. 56, Iss. 10, pp. 6756-6769
Open Access | Times Cited: 34
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Silvia Fanni, Simona Scheggi, Francesca Rossi, et al.
Neurobiology of Disease (2018) Vol. 121, pp. 120-130
Closed Access | Times Cited: 32

Scroll to top